Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sanofi SNY
$54.01
-$0.36 (-0.67%)
На 18:00, 12 мая 2023
-11.00%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
135304234701.00000000
-
week52high
57.82
-
week52low
36.91
-
Revenue
45389000000
-
P/E TTM
57
-
Beta
0.40648800
-
EPS
3.72000000
-
Last Dividend
1.90000000
-
Next Earnings Date
27 апр 2023 г. в 04:00
Описание компании
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Deutsche Bank | Hold | Sell | 12 авг 2022 г. |
| SVB Leerink | Outperform | Market Perform | 27 сент 2021 г. |
| Deutsche Bank | Sell | 15 янв 2021 г. | |
| Goldman Sachs | Buy | Neutral | 11 мар 2020 г. |
| Argus Research | Buy | Buy | 19 февр 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
Investors Business Daily
12 мая 2023 г. в 04:50
Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. The results could stoke Sanofi stock.
Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate
Market Watch
11 мая 2023 г. в 14:46
A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.
7 Blue-Chip Stocks to Buy in May 2023
InvestorPlace
04 мая 2023 г. в 18:01
While large-capitalization enterprises don't offer much excitement, current circumstances may call for the best blue-chip stocks to buy. Frankly, it's getting a little bit toasty on Wall Street, which is why stability may come at a premium.
SNY or LLY: Which Is the Better Value Stock Right Now?
Zacks Investment Research
03 мая 2023 г. в 12:55
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Sanofi SA (SNY) Q1 2023 Earnings Call Transcript
Seeking Alpha
27 апр 2023 г. в 14:27
Sanofi SA (SNY) Q1 2023 Earnings Call Transcript.